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TCT-306
Use Of The Novel Sideguard Dedicated Bifurcation Stent; A Real World
Experience
Mamas Mamas, Sanjay Sastry, Karen Palmer, Magdi El-Omar, Doug Fraser, Farzin
Fath-Ordoubadi
Manchester Heart Centre, Manchester, United Kingdom
Background: PCI treatment of bifurcation disease is technically challenging and
associated with both lower procedural success and higher MACE rates than observed
in non-bifurcation lesions. The optimal treatment strategy for bifurcation lesions
remains unclear and dedicated bifurcation stents have been developed to address some
of the challenges associated with bifurcation lesions. The Sideguard stent is a novel
nitinol self-expanding dedicated bifurcation stent that flares proximally at the ostium
of the side branch (SB) thereby achieving full ostial coverage. The aim of this study is
to report clinical utility and outcomes of the Sideguard stent in patients undergoing
treatment to bifurcation coronary lesions in a real world setting in a large tertiary UK
centre.
Methods: Data was prospectively collected from over a 1-year period from March
2010-2011.
Results: Over a 1 year period, 1630 PCI procedures involving 1954 lesion were
performed in our centre of which 315 were bifurcation lesions (16.1%); 246 were
treated with single stent strategy (78.1%) whilst 69 were treated with 2 stent strategy
(21.9%). 40 lesions were treated with the Sideguard dedicated side branch stent in 38
patients. The mean age of the patients was 58.2±12.0 years old (mean±SD) and 35/40
lesions were true bifurcation lesions (87.5%). The sideguard stent was successfully
used in all 38 cases including several that would have been technically difficult using
conventional bifurcation techniques. There were no peri-procedural complications and
MACE event rates were 5.3% at 1 year (TVR at 3 months in 1 patient and MI at 7
months in a second patient).
Conclusion: In one of the largest clinical experiences to date, the Sideguard stent can
be used to treat complex bifurcation lesions in a straight forward manner, with excellent
short and long term clinical outcomes and is not subject to the limitations associated
with conventional bifurcation PCI techniques such as maintenance of access to the SB,
having a guidewire secured in the main vessel throughout the procedure and ability to
fully cover the ostium of the SB.
TCT-307
Impact of Acute Coronary Syndrome on Clinical Outcomes in Patients with
Coronary Bifurcation Lesions Treated with Drug-Eluting Stents
Pil Sang Song, Kye Taek Ahn, Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi,
Jin-Ho Choi, Sang Hoon Lee, Hyeon-Cheol Gwon
Cardiology, Samsung Medical Center, Seoul, Republic of Korea
Background: No prior study has addressed the impact of clinical presentations on
outcomes in patients with coronary bifurcation lesions. Therefore, we examined the
independent prognostic value of acute coronary syndrome (ACS) in patients with
coronary bifurcation lesions treated with drug-eluting stents (DES).
Methods: We enrolled 1,668 patients, using data from “The COBIS (Coronary
Bifurcation Stenting) registry”. The primary objective was to compare the 2-year
cumulative risk of major adverse cardiac events (MACE) in patients with ACS to those
with stable angina.
Results: Nine hundred sixty nine patients presented with ACS and 699 patients
presented with stable angina. Baseline clinical, angiographic and procedural
characteristics of the 2 groups are listed in Table. Two-year MACEs were 7.3% in
patients with ACS and 5.2% in stable angina patients (p=0.042), mainly driven by
higher TLR rate. However, cardiac death, MI, TLR, and stent thrombosis (ST) were
1.1%, 1.4%, 5.5%, and 0.6% in patients with ACS, respectively, and 0.6%, 1.0%, 3.9%,
and 0.7% in patients with stable angina (for cardiac death, p=0.21; for MI, p=0.36; for
TLR, p=0.08; for ST, p=0.87). ACS had a borderline statistical significance (adjusted
HR 1.49, 95% CI 0.99-2.25, p=0.06) in predicting MACEs. In the ACS patients cohort,
baseline lesion length in side branch (adjusted HR 1.04, 95% CI 1.01-1.07, p=0.022),
paclitaxel-eluting stents in main vessel (adjusted HR 2.02, 95% CI 1.21-3.40, p=0.008),
and final kissing balloon dilatation (adjusted HR 1.88, 95% CI 1.10-3.21, p=0.021)
were independent predictors of MACEs.
Clinical, angiographic, and procedural characteristics
Conclusion: Patients with bifurcation lesions and ACS treated with DESs have a
tendency to increase the risk of MACEs during the 2-year follow-up after intervention
compared to stable angina patients.
TCT-308
Left Main Bifurcation Stenting: Long Term Followup of Simultaneous Kissing
Stents in 140 Consecutive, Unselected Patients
Julian Gunn, Anjan Siotia, Chris Malkin, Tushar Raina, Allison C Morton
Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom
Background: Stenting the left main stem (LMS) is accepted. Most lesions involve the
bifurcation. Whilst a single stent strategy is established generally, this is not the case
at the LMS bifurcation. We present the results of simultaneous kissing stenting (SKS)
for this indication.
Methods: A single operator registry. We treated consecutive, unselected patients with
bifurcation LMS disease ± multi-vessel disease with SKS and maximal
revascularisation, from 2004, using drug-eluting stents (DES) and recorded clinical
status at baseline, 30d, and 1 and 2 years
Results: 140 patients completed 1 year follow-up. Mean age was 67 years, 75% were
male, 35% were non-elective, the New York Risk Score estimation of in-hospital
mortality was median 0.6% (range 0.1-64) and EuroSCORE 2.6 (0.9-67). SKS were
deployed successfully in 100% cases and DES in 94.3%. 2.0±0.9 other vessels were
diseased and 1.9±0.8 treated. The 30d mortality was 6% [NY Risk 21(0.6-64)] and all
deaths were in the acute coronary syndromes. The mortality rate at 1 year was 11%
(2% elective), and at 2 years 13%. 8/10 out-of-hospital deaths were attributable to
probable (1) or possible (7) stent thrombosis and 7 were not surgical candidates.
Ischemia-driven TVR was 4% at 1 year, and 6% at 2 years. There was 1 stroke, 1
STEMI and no emergency CABG at 2y
SKS of 1,1,1 LMS bifurcation stenosis
Conclusion: This is the largest registry of patients treated for LMS bifurcation disease
with SKS in the world. This technique is simple, feasible and practical, including
patients in extremis or unsuitable for CABG. Long-term results are excellent, and
dependent upon clinical status
TCT-309
Outcomes Following Unprotected Left Main Stenting with Everolimus-Eluting
Stents: the Milan Experience
Gill Louise Buchanan1, Alfonso Ielasi1, Alaide Chieffo1, Matteo Montorfano1, Cosmo
Godino1, 2, Azeem Latib1, 2, Mauro Carlino1, Antonio Colombo1, 2
1Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy;
2EMO-GVM Centro Cuore, Columbus, Milan, Italy
Background: Second-generation drug-eluting stents for the treatment of coronary
artery disease (CAD) are believed not only to be more effective but also safer. Our aim
was to assess the clinical outcomes after everolimus-eluting stent (EES) implantation
in patients undergoing percutaneous coronary intervention for unprotected left main
CAD.
Methods: All consecutive patients from our single-center prospective registry treated
for unprotected critical left main stem stenosis with EES implantation from October
2006 to June 2010 were analyzed. The study endpoints were all-cause mortality,
myocardial infarction (MI), major adverse cardiac event (MACE), target vessel
revascularization (TVR), target lesion failure (TLF) and target lesion revascularization
(TLR).
Results: A total of 62 patients were included: the mean age was 67.9 ± 11.4 years and
75.8% were male. The median clinical follow-up was 723.5 days (interquartile range
265.8–1073.0 days). 53.2% underwent PCI with Xience V/Xience Prime (Abbott
Vascular, Redwood City, California, USA) and 46.8% with Promus/Promus Element™
(Boston Scientific, Natick, MA, USA). 43.5% of patients had left main stenosis
associated with triple vessel coronary artery disease and the mean left ventricular
ejection fraction was 55.8 ± 8.1%. Regarding the procedure, 21.0% had an intra-aortic
balloon pump inserted prior to intervention and intravascular ultrasound guidance was
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utilized in 58.1% of cases. Furthermore, a 2 stent strategy was used as the initial
strategy in 40.3% of procedures with final kissing balloon inflation successfully
performed in 74.2%. At 30 days, there was one (1.6%) incidence of TLF, with no other
adverse events. Overall, all cause mortality occurred in 6.5% at follow-up with no MI
or definite/ probable stent thrombosis. Moreover, MACE occurred in 21.0% of patients,
with TVR in 16.1%, TLF in 4.8% and TLR in 4.8%.
Conclusion: The new EES appear to be safe and effective for the treatment of
unprotected left main stem stenosis at median follow-up of 723.5 days. Clearly this
needs to be demonstrated at longer-term follow-up.
TCT-310
Treatment of bifurcations with the dedicated Sideguard nitinol stent compared
with conventional 2-stent strategies
Nicolas Foin1, Carlo Di Mario1, Ajay K Jain2
1Imperial College and Royal Brompton Hospital, London, United Kingdom; 2Barts
and The London NHS Trust, London, United Kingdom
Background: Clinical observations revealed that strut malapposition and Side Branch
(SB) occlusion is common after bifurcations treatment with PCI. Current techniques
for bifurcation stenting often fail to ensure scaffolding of the SB and complete
apposition of stent struts in the bifurcation. Struts floating in the ostium can disturb
blood flow and increase risk of focal restenosis and stent thrombosis, limiting the
success of stent procedures in bifurcations lesions.
Methods: The dedicated Sideguard stent (Cappella Medical Device, Galway, Ireland)
was deployed as SB stent in 2 coronary bifurcation bench models (45° and 70° SB
angle). Commercially available drug eluting stents were used as Main Vessel stents
and malapposition quantified from micro-CT with the Sideguard dedicated SB nitinol
stent (2.5mm and 2.75mm, n=5) was compared with conventional 2-stent stenting
techniques (crush, n=5; culotte, n=3 and t-stenting, n=2).
Results: Rate of malapposed struts within the bifurcation after kissing balloon post-
dilatation using the same balloon sizes and inflation pressure was on average 36.7 ±
8.6 % with conventional techniques, reduced to 16.4 ± 7.5 % with the Sideguard
(p=0008). Area of the SB ostium jailed by stent struts was reduced to 8.3 % when using
the Sideguard compared to an average of 32.8 % after conventional 2-stent techniques
(p=0.0004). Furthermore, the Sideguard device avoid overlap of multiple stent layers,
resulting in less strut malapposition in the Main Vessel proximal to the SB compared
to crush or culotte technique (8.2 % vs. 39.1.%, p=0.0018 and 26.1 %, p=0.024).
Conclusion: Use of the Sideguard as SB stent may offer complete stent scaffolding of
the SB ostium while reducing struts malapposition in the bifurcation ostium and
proximal to the SB compared to conventional 2-stent approaches.
TCT-311
Healing Responses After Bifurcation Stenting with the Dedicated TRYTON
Side-Branch Stent in Combination with XIENCE V Stents: an Angiography
and Optical Coherence Tomography Study
Christophe L Dubois, Tom Adriaenssens, Giovanni Ughi, Mark Coosemans, Bert
Ferdinande, Peter Sinnaeve, Walter Desmet
University Hospital Leuven, Department of Cardiovascular Diseases, Leuven,
Belgium
Background: There is an ongoing controversy regarding the efficacy and safety of
different bifurcation stenting techniques, and dedicated bifurcation stents have been
proposed as a potential alternative. We evaluated healing responses, as assessed with
optical coherence tomography (OCT), and clinical and angiographic outcome, 9
months after percutaneous coronary intervention (PCI) of coronary bifurcation lesions
with the dedicated TRYTON Side-Branch Stent.
Methods: Consecutive patients with coronary bifurcation lesions and significant
involvement of the side-branch underwent PCI with the TRYTON Stent and an
additional XIENCE V stent in a modified culotte technique. Primary endpoint of the
study was the ratio of uncovered to total stent struts at the lesion site, as assessed with
OCT 9 months after PCI. Secondary endpoints were the rate of in-segment restenosis
and late luminal loss at 9 months, as assessed with quantitative coronary angiography
(QCA). Clinical endpoints included the rate of target lesion revascularization (TLR),
target vessel revascularization (TVR), myocardial infarction (MI), cardiac death, and
stent thrombosis at 1 year.
Results: Between January and June 2010, 20 patients (mean age 68±10y, 65% male,
25% diabetes, 95% LAD/Diagonal) were included. Implantation of the TRYTON stent
was successful in 18 (90%). Failures were due to inability to cross the bifurcation with
TRYTON in 1, TRYTON dislodgment during removal of jailed wire in the other.
Angiographic follow-up was available in 18 (90%) at 9.7±1 months. OCT was
performed in 15 (75%, two additional patients with severe restenosis precluding OCT,
1 without TRYTON stent). At 1 year, 6 patients had undergone TVR (30%), of which
4 were TLR (20%). Three of these restenoses were silent. Four occurred at the proximal
main branch stent edge. Five patients suffered MI (25%), 4 of which were
periprocedural and without clinical consequences. There were no deaths nor stent
thromboses.
Conclusion: In patients with complex bifurcation anatomy, a TLR rate of 20% was
seen after implantation of the dedicated first generation TRYTON Side-Branch Stent
in combination with XIENCE V stents. OCT and QCA may help to understand healing
responses and failures. Nine months’ OCT and angiographic follow-up will be
presented.
TCT-312
Effect and mechanisms of coronary bifurcation angle from 3-D on clinical
outcomes after percutaneous treatment with stents-results from DKCRUSH-II
trial
Shao-Liang Chen1, Teguh Santoso2, Ya-Wei Xu3, Qiang Fu4, Chitprapai Paiboon5,
Yong Yong Zhou6, Shi-Qing Ding7, Tak W Kwan8
1Nanjing First Hospital, Nanjing Medical University, Nanjing, China; 2Medistra
Hospital, University of Indonesia Medical School, Jakarad, Indonesia; 3Shanghai
10th People’s Hospital, Shanghai, China; 4Xuzhou Central Hospital, Xuzhou, China;
5Bangkok General Hospital, Bangkok, Thailand; 6Zhangjiagang People’s Hospital,
Zhangjiagang, China; 7Huainan Xinhua Hospital, Huainan, China; 8Beth Israel
Hospital, NY, NY
Background: The role of bifurcation angle (BA) in predicting clinical outcomes after
stenting bifurcation lesions remains to be unclear. The aim of the present study was to
investigator the dynamic change of BA and its predictive value for patients with
coronary bifurcation lesions treated by stents.
Methods: 347 patients were completely studied from our DKCRUSH-II study. BA
was calculated by 3-D quantitative coronary analysis. Primary endpoint was the
occurrence of composite major adverse cardiac events(MACE) at 12-month, including
cardiac death, myocardial infarction(MI) and target vessel revascularization(TVR).
End point was the rate of binary restenosis and stent thrombosis at the end of clinical
follow-up.
Results: Stenting was associated with increase of proximal BA(153.660±21.490) and
the reduction of distal BA. The cut-off value of distal BA for predicting MACE was
600. Distal BA in <600 group had slight reduction after stenting(-1.96±13.580 vs. -
12.12±23.580, p<0.001); two-stent technique was associated with significant reduction
of distal BA (-4.05±14.200),compared to PS group[1.55±11.73,p=0.003); the TLR,
TVR and MACE rate was 16.5%,19.0% and 21.5% in one-stent group (n=79),
compared to 3.8% (p=0.002),7.5%(p=0.016) and 9.8%(p=0.024) in two-stent group
(n=133), respectively; further, the rate of TLR, TVR and MACE in DK group (n=108)
was 2.8%, 6.5%, and 8.3%, compared to 14.4%, 17.3%, and 20.2% in PS group
(p=0.003, =0.019, and =0.017). Among patients in≥600 group, there were no
differences in distal BA, ST, MI, MACE, death, TLR, TVR between one-vs. two-stent
groups; after stenting procedure, there was only slight change of distal BA in LAD-
LCX subgroup (from 88.540±21.330 at baseline to 82.440±31.720 post-stenting),
compared to either LAD-D, or LCX-OM,or RCAd (all p<0.001).
Conclusion: Complex stenting was associated with significant reduction of distal BA.
Two-stent, as DK crush stenting, had reduced rate of MACE in patients in <600 group,
compared to one-stent technique.
TCT-313
Clinical Outcomes of Left Main Crossover Stenting without Opening of Left
Circumflex Coronary Artery
Homyung Lee, Changwook Nam, Hyunok Cho, Houngwon Shin, Yunkyeong Cho,
Hyuckjun Yoon, Seungho Hur, Hyoungseob Park, Hyungseop Kim, Yoonnyun Kim,
Kwonbae Kim
Keimyung university dongsan medical center, Daegu, Republic of Korea,
Democratic People’s Republic of Korea
Background: Simple crossover stenting in non-left main (LM) bifurcation lesion
without opening of stent strut in the ostium of side branch demonstrated a favorable
outcome. However the safety and efficacy of the same strategy for LM crossover
stenting has not been validated yet.
Methods: Among the patients who successfully underwent LM to LAD crossover
stenting due to LM or ostial left anterior descending coronary artery (LAD) disease,
the clinical outcomes of the patients with non-significant residual stenosis (<70%) in
ostial LCX after stenting were evaluated. The 3-year outcome analyzed by the
composite of cardiac death,, myocardial infarction, repeat revascularization, and stent
thrombosis.
Results: Among the included 106 patients, 88 (83%) patients were deferred without
any additional procedure in ostial LCX. Preinterventional and post-stent % diameter
stenosis (DS) of ostial LCX were 23±14% and 33±16%, respectively (p<0.001). The
rate of MACE was 11.4 % (cardiac death 4.5%, myocardial infarction 2.27%, repeat
revascularization 9.1%, and stent thrombosis 2.27%, respectively). Purely ostial LCX
related MACE was 20%. Event free survival curve was obtained (see the attached
figure).
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